Onkologie. 2014:8(5):234-235

Case report of a patient with metastatic renal cell carcinoma and idiopathic thrombocytopenic

Dagmar Brančíková, Zdeněk Mechl, Yvona Brychtová
Interní hematologická a onkologická klinika FN Brno &ndash, Bohunice

purpura treated with sunitinib

In a patient with metastatic renal cell carcinoma, concomitantly treated with corticoids because of idiopathic thrombocytopenic purpura

(ITP), an unusually long survival of 70 months with minimal toxicity has been achieved using sunitinib. In patients with renal cell

cancer toxicity of systemic therapy could be a serious and limiting factor. In this patient with serious comorbidity, therapy with sunitinib

resulted in significant clinical result without any major toxicity.

Keywords: sunitinib, metastatic renal cell carcinoma, idiopathic thrombocytopenic purpura

Published: October 16, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brančíková D, Mechl Z, Brychtová Y. Case report of a patient with metastatic renal cell carcinoma and idiopathic thrombocytopenic. Onkologie. 2014;8(5):234-235.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Májek O, Mužík J, et al. Vývoj epidemiologie zhoubných nádorů prsu u žen dle Nových dat Národního onkologického registru ČR a dalších datových zdrojů. Praktická Gynekologie. 2013; 17(1): 31-39.
    2. Matoušková M, Abrahámová J, Drlík P, et al. Praktická urologie v kazuistikách. 2013: 232.
    3. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832. Go to original source... Go to PubMed...
    4. Oh WK, McDermott D, Porta C, et al. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatments patterns in clinical practice from a global medical chart review. Int J Oncol 2014; 44(1): 5-16. Go to original source... Go to PubMed...
    5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2): 115-124. Go to original source... Go to PubMed...
    6. Červínek L, Doubek M, Mayer J. Idiopathic thrombocytopenic purpura (ITP) - analysis of its prevalence, diagnostics and therapy in the South Moravian Region. Acta Haematologica 2009; 94(Suppl 2): 522.
    7. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345: 1655-1659. Go to original source... Go to PubMed...
    8. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 2011; 22: 1048-1053. Go to original source... Go to PubMed...
    9. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell Carcinoma for cytoreductive nephrectomy? Cancer 2010; 116: 3378-3388. Go to original source... Go to PubMed...
    10. Singer A, Gopal NG, Srinivasan R. Update on Targeted Therapies for Clear Cell Renal Cell Carcinoma Curr Opin Oncol. May 2011; 23(3): 283-289. Go to original source... Go to PubMed...
    11. Zagoria RJ, Pettus JA, Rogers M, et al. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology. 2011; 77: 1393-1397. Go to original source... Go to PubMed...
    12. Ramirez D, Ma YB, Bedir S, et al. Laparoscopic radiofrequency ablation of small renal tumors: Long-term oncologic outcomes. J Endourol. 2014; 28: 330-334. Go to original source... Go to PubMed...
    13. Bhojani N, Jeldres C., Patard JJ, et al. Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma European Urology, Volume 53, Issue 5, Pages 917-930.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.